Frequently Asked Questions
What is Gamida Cell?
Gamida Cell is an Israeli cell therapy company founded in 1998 finder.startupnationcentral.org: Gamida Cell - Israeli Startup Profile (Startup Nation Finder, 2024) (outside source) that developed Omisirge, a NAM modified expanded cord blood therapy fda.gov: NAM modified expanded cord blood product (outside source) for stem cell transplantation. FDA materials describe Omisirge as the first FDA approved expanded cord blood fda.gov: OMISIRGE FDA Page (FDA, 2023-2025) (outside source).
Why did Gamida Cell file for chapter 11?
The company faced a combination of a delayed PDUFA date, slow commercialization, and negative cash flow around $7 million per month stocktitan.net: Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results (Stock Titan, 2024-03) (outside source), which constrained liquidity and pushed it toward a debt supported restructuring, as described in the First Day Declaration.
How fast was the chapter 11 case?
The prepack was confirmed nine days after filing. The petition was filed May 13, 2024 and the Confirmation Order was entered May 22, 2024, with an effective date two days later.
What happened to the $75 million convertible notes?
Highbridge held the 5.875% convertible senior notes and converted that $75 million principal globenewswire.com: Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management (GlobeNewswire, 2024-03-27) (outside source) into 100% of the reorganized equity under the plan. The conversion took the company private and aligned ownership with the primary lender.
What is Omisirge and why is it important?
Omisirge (omidubicel-onlv) is the first FDA approved expanded cord blood product fda.gov: OMISIRGE FDA Page (FDA, 2023-2025) (outside source) for stem cell transplantation. The product received breakthrough therapy and priority review fda.gov: NAM modified expanded cord blood product (outside source) designations, and the manufacturing profile is described in FDA materials and the approval release. The restructuring was designed to keep commercialization moving while the capital structure was reset.
What is the exit facility?
The exit facility is a first lien credit facility with $49 million plus in commitments, including a $30 million new money tranche, a tranche allocated to secured note holders, and a $15 million delayed draw component. The term sheet sets pricing at SOFR plus 850 basis points with a 2.00% floor and a five year maturity (Plan Supplement term sheet).
Why was a chapter 15 case needed?
The chapter 15 proceeding recognized and enforced the Israeli Part X debt arrangement for the parent company in the United States. The Recognition Order and Enforcement Order provided US effect to the Israeli confirmation order and included section 1145 relief for the CVR issuance.
What did shareholders receive?
Existing equity interests were canceled, but former shareholders received CVRs capped at $27.5 million globenewswire.com: Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management (GlobeNewswire, 2024-03-27) (outside source).
Did Gamida Cell delist from Nasdaq?
Yes. Reporting on the restructuring indicates the company delisted and became privately held en.globes.co.il: Gamida Cell to delist as Highbridge takes full ownership (Globes, 2024-05) (outside source) after Highbridge took full ownership.
Who is the claims agent for Gamida Cell?
Kroll Restructuring Administration LLC serves as the claims and noticing agent. The firm maintains the official claims register and distributes case notifications to creditors and parties in interest, as reflected in the claims agent Retention Application Dkt. 20.
For more bankruptcy case analyses and restructuring insights, visit ElevenFlo's bankruptcy blog.